Immunicum AB (DE:1YG0)

FRANKFURT:1YG0

1YG0

Immunicum AB

RESEARCH TOOLSreports

Immunicum AB (1YG0) Price & Analysis

1 Followers

1YG0 Stock Chart & Stats

€0.49

-€0.01(-1.68%)

At close: Jan 08 4:00 PM EST

€0.49

-€0.01(-1.68%)

Day’s Range― - ―

52-Week Range€0.35 - €0.87

Previous CloseN/A

Volume0.00

Average Volume (3M)16.00

Market Cap

€31.40M

Enterprise Value€223.69M

Total Cash (Recent Filing)€74.13M

Total Debt (Recent Filing)€18.67M

Price to Earnings (P/E)―

Beta0.27

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.90

Shares Outstanding62,584,580

10 Day Avg. Volume50

30 Day Avg. Volume16

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)0.50

Price to Sales (P/S)0.00

P/FCF Ratio-3.57

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.15

Revenue Forecast (FY)€230.28K

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthLow leverage materially reduces insolvency risk and extends the company's runway for clinical programs. A stronger balance sheet gives flexibility to fund R&D via equity or partnerships, withstand negative operating cash flow longer, and negotiate non-dilutive deals from a position of relative strength.

Clinical-stage Immuno-oncology FocusA concentrated clinical-stage platform in cell-based immunotherapies provides durable strategic focus and technical expertise. In immuno-oncology, successful clinical milestones can unlock high-value partnerships, milestone payments, or licensing, making the focused pipeline a structural positive for long-term value creation.

Improving Cash Burn TrendA declining cash burn trend improves funding runway and reduces the frequency and size of financing needs. This structural improvement, if sustained, increases the probability of reaching clinical inflection points without severe dilution and supports more orderly partnership or licensing negotiations.

Bears Say

Revenue CollapseNear-zero revenue indicates the company is not generating recurring commercial cash flow and remains dependent on external funding. Over months, this limits strategic options, increases dilution risk, and means corporate value hinges on binary clinical or transaction outcomes rather than steady business performance.

Persistent Negative Cash FlowChronic negative operating and free cash flow erodes cash reserves and forces reliance on equity or deal funding. This structural cash-generation shortfall constrains investment flexibility, heightens refinancing risk, and can compel strategic trade-offs that slow development or reduce long-term optionality.

Large Operating Losses And Negative ReturnsSustained operating losses and negative ROE reflect value erosion and a lack of profitability trajectory. Over time, continued losses can deplete equity, weaken bargaining power with partners, and make it harder to attract non-dilutive capital, increasing the risk that the company must pursue unfavorable financing or asset sales.

1YG0 FAQ

What was Immunicum AB’s price range in the past 12 months?

Immunicum AB lowest stock price was €0.35 and its highest was €0.87 in the past 12 months.

What is Immunicum AB’s market cap?

Immunicum AB’s market cap is €31.40M.

When is Immunicum AB’s upcoming earnings report date?

Immunicum AB’s upcoming earnings report date is Aug 20, 2026 which is in 62 days.

How were Immunicum AB’s earnings last quarter?

Immunicum AB released its earnings results on May 08, 2026. The company reported -€0.031 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.031.

Is Immunicum AB overvalued?

According to Wall Street analysts Immunicum AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immunicum AB pay dividends?

Immunicum AB does not currently pay dividends.

What is Immunicum AB’s EPS estimate?

Immunicum AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immunicum AB have?

Immunicum AB has 62,584,580 shares outstanding.

What happened to Immunicum AB’s price movement after its last earnings report?

Immunicum AB reported an EPS of -€0.031 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.226%.

Which hedge fund is a major shareholder of Immunicum AB?

Currently, no hedge funds are holding shares in DE:1YG0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immunicum AB

Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.